Zacks Small Cap Research – SPGC: Sacks Parente Reports Preliminary Financial Results That Were Above Our Expectations – Go Health Pro

By Thomas Kerr, CFA NASDAQ:SPGC READ THE FULL SPGC RESEARCH REPORT On January 27, 2025, Sacks Parente Golf (NASDAQ:SPGC) provided preliminary financial results for the 4th quarter of 2024 and full year 2024. Revenue is expected to be between $1.1 million – $1.3 million in the 4th quarter of 2024, an increase of 882% … Read more

Zacks Small Cap Research – ENSC Continues to Announce Potential Life-Changing Results – Go Health Pro

By Brad Sorensen, CFA NASDAQ:ENSC READ THE FULL ENSC RESEARCH REPORT Ensysce Biosciences (NASDAQ:ENSC) is a clinical stage company that is developing treatments designed to have the same pain-relieving capabilities as opioids but come with the ability to inhibit abuse and overdoses. Opioid abuse is a national crisis, with the CDC estimating over 75,000 deaths … Read more

Zacks Small Cap Research – EZFL: Recent M&A Expected to Enhance Growth Prospects, as Footprint & Fleet Expand – Go Health Pro

Zacks Small Cap Research – EZFL: Recent M&A Expected to Enhance Growth Prospects, as Footprint & Fleet Expand – Go Health Pro

By M. Marin NASDAQ:EZFL Advancing strategy to be a leading on-demand mobile fueling company… EzFill Holdings (NASDAQ:EZFL) provides a mobile fuel delivery service that offers convenience to owners of commercial fleets and consumer vehicles. Its target market ranges from individual automobile owners to business fleets. The company brings refueling to the vehicles at their primary … Read more

Zacks Small Cap Research – EDSA: IND Expected in 2025 for EB06 for the Treatment of Vitiligo… – Go Health Pro

Zacks Small Cap Research – EDSA: IND Expected in 2025 for EB06 for the Treatment of Vitiligo… – Go Health Pro

By David Bautz, PhD NASDAQ:EDSA READ THE FULL EDSA RESEARCH REPORT Business Update Advancing EB06 for Treating Vitiligo Edesa Biotech, Inc. (NASDAQ:EDSA) is planning for a Phase 2 study of its anti-CXCL10 monoclonal antibody for the treatment of moderate-to-severe non-segmental vitiligo patients. Vitiligo is a disease that causes areas of the skin to lose color, … Read more

Zacks Small Cap Research – CBAT: Positive year-end news countered by continued tariff concerns for battery companies. – Go Health Pro

By Brian Lantier, CFA NASDAQ:CBAT READ THE FULL CBAT RESEARCH REPORT CBAK (NASDAQ:CBAT) has made a number of announcements recently which may not be fully appreciated by the market and which we believe that the shares currently provide an opportunity for patient investors seeking growth at a reasonable price. • In late December, CBAK noted that … Read more